Truist Securities has initiated coverage on Nuvation Bio Inc (NUVB), assigning the company a Buy rating. This marks the firm's first assessment of Nuvation Bio, which focuses on developing innovative therapies to address unmet needs in oncology.
Headquartered in San Francisco, California, Nuvation Bio is dedicated to creating differentiated therapeutic candidates. The company’s portfolio includes taletrectinib, a selective ROS1 inhibitor for treating ROS1-positive non-small cell lung cancer, and safusidenib, a targeted inhibitor of mutant isocitrate dehydrogenase 1. Other programs include NUV-1511, a drug-drug conjugate, and NUV-868, a BET inhibitor.
As of November 23, 2025, Nuvation Bio's stock is priced at $7.41, with a market capitalization of $2.5 billion. The company reported an EPS of -0.64 over the trailing twelve months. Upcoming earnings are anticipated on August 5, 2026, with estimated EPS of -0.17 and revenue of $37.6 million.
Analyst ratings serve as professional opinions shaped by extensive research and financial modeling. While they offer valuable insights, these assessments are based on assumptions that may not always hold true. Investors should consider a variety of factors, including company fundamentals and market trends, when making decisions. Analyst views are just one piece of the puzzle in the investment landscape.
The recent action by Truist underscores a growing consensus among analysts, with a total of 14 ratings reflecting 4 Strong Buy, 9 Buy, and 1 Hold. This consensus indicates a generally favorable outlook for Nuvation Bio as it continues to navigate the competitive pharmaceutical landscape.